Erasin

Overview

Erasin is a potent Erlotinib ( HY-50896 )-resistance antagonizing STAT3 inhibitor with IC 50 s of 9.7 and 24 μM against STAT3 and STAT1 , respectively. Erasin induces cancer cells apoptosis .

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > STAT | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-115594
• CAS No.: 2256056-21-8
• Molecular Formula: C20H19N3O3
• Molecular Weight: 349.38
• Purity: 96.02%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution
• Availability: In-stock

Source

Original product source